Gain Therapeutics (GANX) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to -$0.15.
- Gain Therapeutics' EPS (Weighted Average and Diluted) rose 1176.47% to -$0.15 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.61, marking a year-over-year increase of 4454.55%. This contributed to the annual value of -$1.0 for FY2024, which is 4140.72% up from last year.
- Latest data reveals that Gain Therapeutics reported EPS (Weighted Average and Diluted) of -$0.15 as of Q3 2025, which was up 1176.47% from -$0.19 recorded in Q2 2025.
- In the past 5 years, Gain Therapeutics' EPS (Weighted Average and Diluted) registered a high of -$0.15 during Q3 2025, and its lowest value of -$0.62 during Q2 2023.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.3 (2021), whereas its average is -$0.33.
- In the last 5 years, Gain Therapeutics' EPS (Weighted Average and Diluted) tumbled by 5600.0% in 2021 and then surged by 5476.19% in 2025.
- Quarter analysis of 5 years shows Gain Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.26 in 2021, then plummeted by 50.0% to -$0.39 in 2022, then grew by 25.64% to -$0.29 in 2023, then grew by 5.32% to -$0.27 in 2024, then soared by 45.37% to -$0.15 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.15 in Q3 2025, compared to -$0.19 in Q2 2025 and -$0.16 in Q1 2025.